Brokerages predict that Aratana Therapeutics Inc (NASDAQ:PETX) will report sales of $6.98 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Aratana Therapeutics’ earnings. The highest sales estimate is $7.80 million and the lowest is $5.53 million. Aratana Therapeutics posted sales of $4.04 million in the same quarter last year, which suggests a positive year-over-year growth rate of 72.8%. The company is scheduled to report its next earnings results on Thursday, May 2nd.
On average, analysts expect that Aratana Therapeutics will report full-year sales of $35.12 million for the current fiscal year, with estimates ranging from $26.66 million to $39.40 million. For the next financial year, analysts anticipate that the business will report sales of $72.60 million, with estimates ranging from $56.71 million to $91.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Aratana Therapeutics.
Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.06). The business had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $6.53 million. Aratana Therapeutics had a negative net margin of 41.57% and a negative return on equity of 14.78%.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Toth Financial Advisory Corp acquired a new position in shares of Aratana Therapeutics in the first quarter worth $30,000. Truvestments Capital LLC acquired a new position in shares of Aratana Therapeutics in the first quarter worth $25,000. Adams Asset Advisors LLC acquired a new position in shares of Aratana Therapeutics in the first quarter worth $36,000. Deutsche Bank AG increased its stake in shares of Aratana Therapeutics by 21.1% in the fourth quarter. Deutsche Bank AG now owns 176,187 shares of the biopharmaceutical company’s stock worth $1,079,000 after acquiring an additional 30,711 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Aratana Therapeutics by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 526,329 shares of the biopharmaceutical company’s stock worth $3,226,000 after acquiring an additional 91,968 shares during the last quarter. 68.13% of the stock is currently owned by institutional investors and hedge funds.
Shares of PETX traded down $0.03 during mid-day trading on Tuesday, reaching $3.50. The company’s stock had a trading volume of 181,832 shares, compared to its average volume of 260,426. The firm has a market capitalization of $171.41 million, a P/E ratio of -10.94 and a beta of 1.36. Aratana Therapeutics has a 1 year low of $3.30 and a 1 year high of $7.16.
About Aratana Therapeutics
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.
Featured Story: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.